// App-Quantinova.ai

: Safety of the oral JAK3/TEC inhibitor ritlecitinib (PF-06651600) in patients with alopecia areata: results from the ALLEGRO Phase 2b/3, randomized, double-blind, placebo-controlled trial

Researchers

Presenter

  • Brett King

Principal Investigators

  • Jacek C. Szepietowski

  • Paul Farrant

  • Maria Hordinsky

  • Alexre Lejeune

  • Samuel H. Zwillich

  • Dalia Wajsbrot

  • Robert Wolk

Medical Centers

  • Yale University School of Medicine, New Haven, CT

  • Department of Gastroenterology and Hepatology, Wroclaw Medical University, Wroclaw, Poland

  • Department of Dermatology, Brighton General Hospital, University Hospitals Sussex, Brighton, UK

  • Department of Dermatology, University of Minnesota, Minneapolis, MN, USA

  • Pfizer Inc., Paris, France

  • Pfizer Inc, Groton, CT, USA,

  • Pfizer Inc, New York, NY

Locations

  • United Kingdom

  • United States

  • Poland

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Nuclear receptor subfamily 4 group A member 3

  • Janus kinase 3

Drug/Treatment

  • Frovatriptan succinate

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • II

Study Id's

  • NCT03732807

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved